North China Pharmaceutical Group Corp:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:North China Pharmaceutical Group Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10506
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
North China Pharmaceutical Group Corp (NCPC) is a healthcare products provider that manufactures and distributes formulation products, nutrition and health products, raw materials, and veterinary drugs. The company offers sirolimus capsules, clindamycin phosphate injection, mezlocillin sodium for injection, ampicillin sodium for injection, amoxicillin sulbactam pills, amoxicillin dispersible tablets, cyclosporin soft capsule mecobalamin tablets and rocuronium bromide injection. Its nutrition and health products comprise chewable tablets, anyixin tablets, isomaric syrup, xin yan capsule and soft capsule. NCPC offers products in dosage forms of capsules, granules, injections, freeze-dried powder for injection, immunologic and biologic agent, nutrition supplement, tablets, veterinary and biocides products, powder for injection, antineoplastic agents, oral suspension and other formulations. The company markets its products across China. NCPC is headquartered in Shijiazhuang, China.

North China Pharmaceutical Group Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deal Details 9
Equity Offering 9
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
Debt Offering 11
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 11
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 12
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 13
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 14
North China Pharma Announces Public Offering Of Notes For US$73 Million 15
Acquisition 16
NCPC To Sell North China Pharma Huasheng For US$12 Million 16
NCPC To Sell 39% Stake In Shenzhen Medicine Company For US$3 Million 17
NCPC To Acquire Remaining 50% Stake In NCPC Orchid Pharma For US$14 Million 18
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 19
North China Pharmaceutical Group Corp – Key Competitors 20
North China Pharmaceutical Group Corp – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Key Facts 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 11
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 12
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 13
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 14
North China Pharma Announces Public Offering Of Notes For US$73 Million 15
NCPC To Sell North China Pharma Huasheng For US$12 Million 16
NCPC To Sell 39% Stake In Shenzhen Medicine Company For US$3 Million 17
NCPC To Acquire Remaining 50% Stake In NCPC Orchid Pharma For US$14 Million 18
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 19
North China Pharmaceutical Group Corp, Key Competitors 20
North China Pharmaceutical Group Corp, Subsidiaries 21

List of Figures
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

★海外企業調査レポート[North China Pharmaceutical Group Corp:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Covis Pharma Sarl:製薬・医療:M&Aディール及び事業提携情報
    Summary Covis Pharma Sarl (Covis Pharma), a subsidiary of Concordia International Corp is a specialty pharmaceutical company that develops and markets drugs for the treatment of life-threatening conditions and chronic illnesses. The company develops products for central nervous system and rheumatic …
  • Broadcom Inc (AVGO):企業の財務・戦略的SWOT分析
    Broadcom Inc (AVGO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Specialised Therapeutics Australia Pty Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Specialised Therapeutics Australia Pty Ltd (STA) is a biopharmaceutical company that develops and commercializes therapies and technologies for unmet medical needs. The company’s product portfolio includes abraxane, gliolan, oncotype dx, iclusig, oncotype dx prostate and aloxi. Its pipeline …
  • Rubicon Genomics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Rubicon Genomics Inc (Rubicon Genomics), a subsidiary of the Takara Bio Group is a provider of pre-analytical amplification technologies. The company offers various types of kits for whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing, copy number variation (CNV) …
  • Mr. Price Group Ltd.:企業の戦略・SWOT・財務情報
    Mr. Price Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mr. Price Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Ws Atkins Ltd
    Ws Atkins Ltd - Strategy, SWOT and Corporate Finance Report Summary Ws Atkins Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Population Genetics Technologies Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Population Genetics Technologies Ltd (Population Genetics) is a biotechnology company that offers diagnostic test solutions. The company provides products such as diagnostic test kits, HIV diagnostic test systems, and HCV diagnostic test systems. Its diagnostic test kits provide reagent assa …
  • Taiho Pharmaceutical Co Ltd:企業の戦略的SWOT分析
    Taiho Pharmaceutical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Stanbic Ibtc Holdings Plc:企業の戦略・SWOT・財務分析
    Stanbic Ibtc Holdings Plc - Strategy, SWOT and Corporate Finance Report Summary Stanbic Ibtc Holdings Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Japan Post Holdings Co., Ltd.:企業の戦略・SWOT・財務情報
    Japan Post Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Japan Post Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Compania General de Combustibles SA:石油・ガス:M&Aディール及び事業提携情報
    Summary Compania General de Combustibles SA (CGC), a subsidiary of Corporacion America Sudamericana SA is an oil and gas company that produces petroleum products. The company’s products include crude oil, liquefied petroleum gas, natural gas, gasoline and others. It offers services such as domestic …
  • Armune BioScience Inc-医療機器分野:企業M&A・提携分析
    Summary Armune BioScience Inc (Armune) is a medical device company that develops and commercializes molecular diagnostic and prognostic tests. The company uses genomics and proteomics in cancer to identifying specific sets of genes or proteins. It develops protein signature based diagnostic tests fo …
  • Trovagene Inc (TROV)-製薬・医療分野:企業M&A・提携分析
    Summary Trovagene Inc (Trovagene) is a development stage molecular diagnostic company focusing on the development and commercialization of proprietary molecular genetic detection technologies for screening and monitoring cancer and other diseases. Its product portfolio includes liquid biopsy tests t …
  • Volga Gas plc (VGAS):企業の財務・戦略的SWOT分析
    Summary Volga Gas Plc (Volga Gas) is an oil and gas company that provides oil and gas exploration and production services. The company acquires, produces and develops oil, natural gas deposit properties, and others. It owns and operates oil and gas producing assets in Karpenskiy licence area, Pre-Ca …
  • vTv Therapeutics Inc (VTVT):企業の財務・戦略的SWOT分析
    Summary vTv Therapeutics Inc (vTv), formerly TransTech Inc, is a pharmaceutical company that discovers, develops and commercializes human therapeutics. The company offers a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases includ …
  • Offshore Marine Management Limited:企業の戦略的SWOT分析
    Offshore Marine Management Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Hoya Corporation:企業のM&A・事業提携・投資動向
    Hoya Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hoya Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • PetroMaroc Corporation Plc (PMA):企業の財務・戦略的SWOT分析
    Summary PetroMaroc Corporation Plc (Petromaroc), formerly Longreach Oil and Gas Ltd, is an oil and gas exploration and development company that evaluates, acquires, explores and develops oil and gas properties in Morocco. The company holds interests in the Sidi Moktar licence area which includes geo …
  • Ion Beam Applications SA (IBAB)-医療機器分野:企業M&A・提携分析
    Summary Ion Beam Applications SA (IBA) is a medical technology company that develops solutions for the diagnosis and treatment of cancer. It offers monitoring equipment and software that enables hospitals to perform calibration procedures during radiation therapy and radiology. The company focuses i …
  • Mologen AG:企業のM&A・事業提携・投資動向
    Mologen AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mologen AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆